ICA-105574

CAS No. 316146-57-3

ICA-105574( ICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide )

Catalog No. M24250 CAS No. 316146-57-3

ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 88 In Stock
5MG 80 In Stock
10MG 140 In Stock
25MG 297 In Stock
50MG 458 In Stock
100MG 672 In Stock
200MG 918 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ICA-105574
  • Note
    Research use only, not for human use.
  • Brief Description
    ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
  • Description
    ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ICA | 3-nitro-N-[4-phenoxyphenyl]-benzamide
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    hERG
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    316146-57-3
  • Formula Weight
    334.33
  • Molecular Formula
    C19H14N2O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:10 mM
  • SMILES
    C1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Meng J , Shi C , Li L , et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization[J]. European Journal of Pharmacology, 2013, 718(1-3):87-97.
molnova catalog
related products
  • Orphenadrine Citrate

    Orphenadrine Citrate is a skeletal muscle relaxant, it acts in the central nervous system to produce its muscle relaxant effects.

  • Lapatinib ditosylate...

    Lapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.

  • Alflutinib

    Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor.